The success of Sildenafil initially drove a surge for pharma, nevertheless recent changes present a murky outlook for those considering a stake. Lower-cost versions are eating into revenue, and persistent litigation https://saulmowz347718.atualblog.com/47856011/viagra-and-pharma-a-risky-bet